Apogee Therapeutics, Inc. (APGE)
Oxford Ledge is still expanding full research coverage of APGE. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Apogee develops engineered antibody therapies for inflammatory diseases, with lead program in Phase 2 trials for atopic dermatitis.
SEC filings
- 8-K Entry into material agreement; Shareholder vote results; Regulation FD disclosure; Other material event; Financial statements and exhibits 2026-06-22
- 8-K Entry into material agreement; Financial statements and exhibits 2026-06-22
- 8-K Shareholder vote results 2026-06-12
- 8-K Entry into material agreement; Regulation FD disclosure; Financial statements and exhibits 2026-05-27
- 8-K Regulation FD disclosure; Other material event; Financial statements and exhibits 2026-05-27
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for APGE. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open APGE in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.